NOXOPHARM-LIMITED
14.4.2021 14:02:07 CEST | Business Wire | Press release
Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced an international patent application aimed at protecting the use of experimental anti-cancer drug, Veyonda® (idronoxil), in blocking the development of septic shock associated with infections such as COVID-19 and influenza viruses.
Overall, septic shock is believed responsible for an estimated 10 million global deaths per year, with an estimated three million additional deaths due to the current pandemic. So-called ‘long COVID’ symptoms (e.g., long-lasting fatigue, breathing problems, headaches), along with severe organ damage (e.g., limb amputation, diabetes, kidney, and heart failure) and death are all are outcomes associated with septic shock.
Veyonda is being developed as an anti-cancer drug based on immunostimulation and anti-inflammation functions. Its anti-inflammatory action stems from blocking of a signalling pathway called STING that normally serves as trigger for an inflammatory response to repair damaged tissue such as virally-infected lungs. In some individuals, the STING response is inappropriately excessive, pushing the individual over into septic shock. Veyonda is the first drug that blocks STING to be tested in septic shock, including in COVID-19 patients.
Graham Kelly , CEO of Noxopharm, said, “Globally, someone dies every three seconds from septic shock, the same rate as cancer. A cost-effective treatment for septic shock doubles the commercial opportunity for Veyonda.”
About Noxopharm
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.
Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking septic shock.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005036/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Optimum Asset Management’s Investor Summit in Portofino brings together Mike Pompeo, Matteo Renzi and leaders across government, finance and industry to discuss the future of the global economy and geopolitics16.6.2026 09:30:00 CEST | Press release
Mike Pompeo addressed geopolitical risks including China, Iran, Ukraine and Europe-US security cooperation. Matteo Renzi, Edoardo Rixi and senior government representatives joined discussions on European competitiveness, infrastructure and energy. The summit convened institutional investors, entrepreneurs and financial market professionals to discuss the future of the global economy. The first edition of the Optimum Investors Summit – The Portofino Conversation, hosted by European real estate private equity investment firm Optimum Asset Management and its Italian partners Alberto Matta, Rodolfo Misitano, Enrico Imbraguglio and Andrea Suriano, concluded with strong participation from institutional investors (including pension funds), entrepreneurs, government representatives and financial market professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615915564/en/ Alberto Matta, Managing Partner at Optimum Asset Mana
Elite Tech, Accessible Price - Introducing the Logitech G3 Series Mouse and Keyboard for PC Gaming16.6.2026 09:05:00 CEST | Press release
Elite Precision - Unleash pro-grade speed with the G305 X SUPERLIGHT gaming mouse and G316 X 98 gaming keyboard. Featuring the HERO 44K sensor and an 8 kHz report rate, this duo delivers sub-micron accuracy and near-instant response for every player.Boutique Customization - Get that premium "thock" without the DIY hassle. The G316 X 98 features a snap-fit gasket design, hot-swappable switches, and an interactive dot-matrix display for a truly custom feel.The Power Ecosystem - High performance, accessible price. Elevate your setup with the G305 X SUPERLIGHT mouse, G316 X 98 mechanical keyboard, and the plush G325 wireless headset—the ultimate gear for total immersion. Logitech G today announced the expansion of the G3 Series suite of PC Gaming products. Designed to bring pro-inspired performance to more gamers, the extended lineup features the G305 X SUPERLIGHT wireless gaming mouse and the G316 X 98 wired mechanical gaming keyboard. This press release features multimedia. View the full
Ny analyse: AI udfordrer SMV’ers digitale konkurrenceevne16.6.2026 09:01:00 CEST | Pressemeddelelse
AI skaber nye konkurrencevilkår og udfordringer for virksomheder digitalt, og særligt SMV’er har svært ved at følge med udviklingen. Det viser en ny undersøgelse blandt over 10.000 europæiske virksomheder, hvoraf 556 af dem er danske. Virksomheder har aldrig haft adgang til så mange digitale kanaler, men med udviklingen af AI, øget konkurrence og skiftende algoritmer er det digitale landskab blevet mere komplekst end nogensinde før, og vilkårene ændrer sig lige nu hurtigere, end mange kan nå at følge med. En ny omfattende erhvervsundersøgelse fra hosting-virksomheden team.blue, som i Danmark har 220 medarbejdere og 250.000 kunder med kontorer i Skanderborg og København, viser, at det er blevet sværere for virksomheder, særligt SMV’er, at styre deres digitale forretningsvækst. Ifølge undersøgelsen, State of European Business Report 2026, som er foretaget blandt mere end 10.000 virksomheder på tværs af 32 lande, herunder 556 fra Danmark, hvoraf størstedelen er SMV’er, er der opstået et s
Tampere Philharmonic Orchestra Appoints Kristian Sallinen as the Next Chief Conductor16.6.2026 09:00:00 CEST | Press release
Kristian Sallinen has been appointed Chief Conductor and Artistic Director of the Tampere Philharmonic Orchestra. He will begin his three-year term in August 2027, following the tenure of British conductor Matthew Halls. Sallinen will conduct a minimum of 7–8 programmes each season alongside other projects and will become the thirteenth Chief Conductor in the Finnish orchestra’s 96-year history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615800659/en/ Conductor Kristian Sallinen will begin his tenure as the new Chief Conductor of the Tampere Philharmonic Orchestra in August 2027. Photo: Antti Rintala. Sallinen last appeared in Tampere in September 2025, conducting Richard Strauss’s Der Rosenkavalier Suite and Magnus Lindberg’s Concerto for Orchestra. He will return this September to lead a programme of Finnish music by Jean Sibelius, Kaija Saariaho and Väinö Raitio. – I am deeply honoured and grateful for the trust th
ABB Robotics and PSYONIC Use Human-Generated Data to Advance Robotic Dexterity16.6.2026 06:01:00 CEST | Press release
ABB Robotics and PSYONIC collaborate to revolutionize grasping and dexterity, a core capability for Autonomous Versatile Robotics™ ABB GoFa™ helps test PSYONIC’s Ability Hand for robotics, combining touch sensing, compliant design and human-derived training data Dexterity remains a major challenge for industry; improved handling can reduce engineering time by up to 30%¹ ABB Robotics is collaborating with California bionics company, PSYONIC, to advance robotic gripping and dexterity using a new approach that utilizes real-world manipulation data from human prosthetic use. By combining the PSYONIC Ability Hand with an ABB GoFa™ cobot, the collaboration will explore how touch and motion data generated by human prosthetic use can be used to train robots to perform delicate, variable tasks that have traditionally been difficult to automate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612749544/en/ “Human dexterity and the i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom